At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
In Brief
A Phase 2 clinical trial evaluating Emraclidine 15 mg, Emraclidine 30 mg, and 1 other intervention for Schizophrenia. Completed, enrolled 391 participants across 26 sites in 3 countries.
Detailed Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female adult participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Study Details
Timeline
Interventions
Emraclidine 15 mg, oral (tablet), once per day (QD) for 6 weeks
Emraclidine 30 mg, oral (tablet), QD for 6 weeks
Matching placebo, oral (tablet), QD for 6 weeks